logo
logo

Slingshot Biosciences Announces $23 Million In Series A Financing

Slingshot Biosciences Announces $23 Million In Series A Financing

07/22/21, 11:24 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgemeryville
Money raised
$23 million
Round Type
series a
Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing. The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. The new funding will enable Slingshot to accelerate the commercialization of its synthetic cell products spanning controls, diagnostics, and adoptive cell therapies. Adam Wieschhaus, PhD, Director at Northpond Ventures, and Corey Ritter, Senior Associate at ARCH Venture Partners, will join the Board of Directors

Company Info

Company
Slingshot Biosciences
Location
emeryville, california, united states
Additional Info
Slingshot Biosciences develops synthetic cells for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf solution for cell-like reagents that are stable, low-cost, and targeted toward a range of indications and markets. Learn more at www.slingshotbio.com.